Literature DB >> 34922870

Determinants of Plaque Progression Despite Very Low Low-Density Lipoprotein-Cholesterol Levels With the PCSK9 Inhibitor, Evolocumab.

Satoshi Honda, Rishi Puri, Todd Anderson, John J P Kastelein, Danielle M Brennan, Helina Kassahun, Ransi Somaratne, Scott M Wasserman, Steve E Nissen, Stephen J Nicholls.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34922870     DOI： 10.1016/j.jcmg.2021.11.014

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN： 1876-7591


× No keyword cloud information.
  1 in total

1.  Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial.

Authors:  Lorenz Räber; Yasushi Ueki; Tatsuhiko Otsuka; Sylvain Losdat; Jonas D Häner; Jacob Lonborg; Gregor Fahrni; Juan F Iglesias; Robert-Jan van Geuns; Anna S Ondracek; Maria D Radu Juul Jensen; Christian Zanchin; Stefan Stortecky; David Spirk; George C M Siontis; Lanja Saleh; Christian M Matter; Joost Daemen; François Mach; Dik Heg; Stephan Windecker; Thomas Engstrøm; Irene M Lang; Konstantinos C Koskinas
Journal:  JAMA       Date:  2022-05-10       Impact factor: 157.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.